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Abstract: The term “chronic idiopathic urticaria” denotes a spec-
trum of conditions with different poorly understood pathogenetic
mechanisms in which the release of histamine plays a role. Nonse-
dating second-generation H1 antihistamines are postulated to be the
first line of treatment of chronic idiopathic urticaria by national and
international guidelines, but as control is not always achievable with
the usually recommended doses, first-generation sedating antihista-
mines like hydroxyzine and diphenhydramine at high daily doses
(200 mg) have been proposed as an alternative before resorting to
treatment with systemic corticosteroids and other potentially haz-
ardous agents. Our long time experience and recent research give us
grounds to believe that increasing the doses of nonsedating H1
antihistamines up to fourfold improves significantly the chances of
successful treatment. Our data suggest that the urticaria-associated
discomfort is relieved by higher than conventional doses of levoce-
tirizine and desloratadine in about 75% of the patients and that
sedation/somnolence does not seem to be a major deterrent. The
dose increase also improves the urticaria-specific quality of life.
Contrary to the belief that individual patients may benefit from one
antihistamine or another, we demonstrate that the drug with better
ability to suppress the histamine skin effects in experiments in
healthy volunteers (levocetirizine) is also superior in improving the
different aspects of control of chronic urticaria (subjective and
objective symptoms, quality of life) and that increasing its dose of
up to fourfold may even paradoxically reduce the sense of sedation/
somnolence in parallel with the relief of urticaria discomfort.
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DEFINING THE TOPIC
A wide spectrum of different conditions share a seeminglycommon clinical feature: appearance of urticarial lesions.
The latter are described as red, raised, itchy wheals (“nettle
rash,” “hives”) resulting from vasodilatation, increased blood
flow, and increased vascular permeability.1 They have fleet-
ing character and disappear without a trace in less than 24
hours. In a significant proportion of the cases they can be
accompanied by swelling of the deeper cutaneous and sub-
cutaneous tissues referred to as angioedema, tending to re-
gress substantially slower (up to 72 hours). When the wheals
with or without angioedema recur for longer than 6 weeks,
they fall within the definition of chronic urticaria (Fig. 1).
Chronic urticaria (CU) is a relatively common condition,
which has a profound effect on the quality of life of those
suffering.2 The need to establish an optimal approach to this
class of disorders resulted in working out of national and
international guidelines for its diagnosis, classification, pathoge-
netic mechanisms, and management.3,4 As opposed to other
types of urticaria like acute urticaria, physical urticaria, and
urticarial vasculitis that may have identifiable causes and trig-
gers, the nature of chronic spontaneous urticaria remains elusive,
which is reflected in the commonly accepted term chronic
idiopathic urticaria (CIU). In about 45% of the cases of CIU,
signs of autoimmunity can be detected by means of skin tests to
autologous serum or plasma, or by detection of autoantibodies to
IgE or the high-affinity IgE receptor (FcRI) on basophils and
mast cells.4–6 Another clue toward autoimmunity is evidence of
an increased prevalence of antithyroid autoantibodies among
CU patients.7 It appears, though, that identifiable autoimmune
mechanisms do not alter the subsequent treatment approach. The
latest EAACI/GA(2)LEN/EDF/WOA management guideline
grades the strength and quality of the experimental evidence
when formulating recommendations.8 The starting point for
pharmacological treatment is the prescription of nonsedating H1
antihistamines (nsAH) (table 1, adapted from Table in reference 8).
When analyzing the state-of-the-art of urticaria man-
agement, the guidelines have recognized deficits in the sup-
porting evidence. In a recent overview of his extensive
experience in urticaria treatment, Allen Kaplan, a leading
expert in the field of urticaria, lists a number of misconcep-
tions among the medical community and the lay public
related to urticaria management and pinpoints controversies
relating to the use of AH, which need to be addressed by
specifically designed clinical studies.9 The present paper is
focusing exclusively on the treatment of chronic urticaria
with nsAH, as these drugs are suggested as the first line of
treatment, but unresolved issues still remain because of the
relative paucity of reliable evidence.8
THE ROLE OF HISTAMINE IN CIU
Histamine is a low molecular weight amine synthesized
from L-histidine by the enzyme histidine decarboxylase and
plays a vital role in the regulation of many important func-
tions of the organism related to circadian influences, adapta-
tion to the environment, and stress. Conversely, histamine is
intimately implicated in the pathogenesis of allergic and other
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diseases, which develop as a defective systemic trait and may
have different organ expressions. Histamine exerts its multi-
ple effects by coupling to receptors expressed on the mem-
brane of cells in different tissues. Four different receptors
have been identified and sequenced so far denoted sequen-
tially as H1 to H4.10 The histamine effects in the skin asso-
ciated with urticaria, particularly the wheals and the itch, are
mediated through H1 receptors located on nerves and endo-
thelial cells.11 A role in urticaria has been proposed also for
the H4 receptors in the generation of pruritus and eosinophil
chemotaxis.12 The histamine receptors exhibit stereochemical
differences, which can be recognized by different chemical
compounds, referred to as specific receptor agonists. A big
proportion of these invert the original effects of histamine by
rendering the receptor–G-protein complex inactive, which
categorizes them as “inverse” agonists.13 However, as they
abolish the effects of histamine, they are popularly known as
histamine receptor antagonists or antihistamines.
The mechanisms at play in patients with chronic urticaria
are much more complex than just release of histamine from
basophils and mast cells triggered by a variety of pathways.6
Involvement of other mediators like leukotrienes, prostaglan-
dins, kinins, anaphylatoxins, and chemokines is also occurring,
shaping individual patterns in each particular case and determin-
ing the success of treatment.14 A cellular infiltrate similar to a
late-phase IgE-mediated allergic reaction with ensuing therapeu-
tic implications has been extensively reviewed.15 Still, in most
cases histamine has a leading role in the pathogenesis of chronic
urticaria, which is the reason for H1 AH to be proposed as
first-line and mainstay treatment (Table 1).8
PICKING THE BEST ANTIHISTAMINE FOR THE
TREATMENT OF CIU
Within a period of 40 years since 1937, when Bovet
and Staub described the first pharmaceutical formulation to
counter the effects of histamine in a guinea pig, about 40 AH
had been introduced for the treatment of nasal allergic and
skin symptoms. They all had a short plasma half-life, were
not very H1-receptor specific, caused significant central ner-
vous system (CNS) adverse effects, and became subsequently
known as first-generation H1 AH.16 Some of them like hy-
droxyzine and diphenhydramine had proven to be of partic-
ular benefit in urticaria and are still considered as possible
choices in cases resistant to treatment.17 A significant step
forward was the synthesis of more complex compounds with
improved pharmacokinetic and pharmacodynamic profiles:
they hardly penetrated the blood-brain barrier, which makes
them relatively free of the most bothersome adverse CNS
effects (drowsiness, lassitude, dizziness, and incoordination),
possessed higher specificity for the H1 receptors, and had
longer half-life, allowing a once daily dosing regimen.18 They
were referred to as second-generation H1-receptor antago-
nists, and whereas 2 of the earlier compounds (terfenedine
and astemisol) were abandoned because of serious cardiac
side effects, the “newest arrivals” (fexofenadine, deslorata-
dine, and levocetirizine) took up the lead in prescription
practices as “modern” second-generation drugs.
Ideally, an AH drug should bind to a maximal number of
H1 receptors to ensure the best effect. Determinants for this to
happen are the applied dose and the pharmoacokinetic properties
of the separate formulations: bioavailability, plasma half-life,
volume of distribution, and receptor affinity. Following this
rationale, the second-generation nsAH should have a clear cut
advantage over the first-generation ones. This is not, however,
the case in everyday practice where nonexperts treat urticaria
and prescribe first-generation drugs contrary to guidelines.19 At
least in part this is due to the belief that sedation may be helpful
in soothing the itch in urticaria patients.
The debate about the use of first-generation H1 AH is
still alive because of some other arguments prompted by
empirical experience. Thus, Allen Kaplan is favoring high
doses of hydroxyzine and diphenhydramine if doubling the
doses of second-generation nsAH does not achieve satisfac-
tory control of symptoms.9,15,17 In the absence of appropriate
studies to provide conclusive evidence, he backs up his
assertions with compelling reasoning:
Y The relatively lower specificity of the first-generation
AH for the H1 receptors may prove an advantage as they
may exert some additional beneficial effects through
other mechanisms: antimuscarinic, anti–-adrenergic,
antiserotonin effects, and activity against H4 receptors.
Y Sedation, somnolence, and performance impairment
with H1 AH are considered a limitation to their use.
However, unlike other conditions where histamine plays
a role, these features in urticaia patients are intimately
associated with the nature of the disease, as sleep depri-
vation because of nighttime itch can be the real cause
underlying them. Thus, sedating AH may turn out to
have a paradoxal positive effect on the state of alertness.
Y The sedative effects on initial intake are short-lived and
gradually wear off by day 4 of treatment with first-
generation AH.
Y The alternative to sedation would be the prescription of
corticosteroids and other more hazardous and expensive
FIGURE 1. Graphical definition of chronic urticaria.
TABLE 1. EAACI/GA(2)LEN/EDF/WOA Algorithm for
Pharmacological Treatment of CIU8
nsAH
2If symptoms persist after 2 weeks:
nsAH updosing (up to 4 times)
2If symptoms persist after 1–4 weeks:
Add leukotriene antagonist or change nsAH
Exacerbation: systemic steroids (for 3–7 days)
2If symptoms persist after 1–4 weeks:
Add cyclosporine A, H2 antihistamine,
a dapsone, omalizumab
Exacerbation: systemic steroids (for 3–7 days)
aIn the United States, adding H2-receptor antagonist to the H1 antihistamine comes
as a second step in the CU management algorithm.
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drugs like cyclosporine, methotrexate, sulfasalazine, in-
travenous gamma globulin, dapsone, hydroxychloro-
quine, colchicine, and cytoxan, with the ensuing delete-
rious risks in the long run.
This sound logic is backed up by decades of first-
generation AH prescriptions, indicating that really high doses
of some of the older drugs can be used to saturate all skin H1
receptors. Thus, Allen Kaplan advocates that up to 4 50 mg
of hydroxyzine and diphenhydramine should be applied to
increase the chances of success if doubling the standard dose
of nsAH fails. This leads us to a total daily dose of 200 mg
of these first-generations drugs, which is way too high com-
pared with the 20-mg daily dose of cetirizine, if a speculative
approximation of 10 mg of cetirizine corresponding to 30 mg
of hydroxyzine (used in comparative studies) is assumed. The
question emerges whether increasing the dose of nsAH high
enough would prove helpful in controlling the urticaria symp-
toms. Studies with fexofenadine failed to show that increas-
ing the dose from 60 to 240 mg makes a meaningful differ-
ence.20,21 However, a twofold increase of the standard dose of
cetirizine was found effective in patients with cholinergic
urticaria,22 a threefold increase of the cetirizine dose brought
about some benefit in a small proportion of patients with
chronic unremitting urticaria,23 and a fourfold increase of the
recommended dose of desloratadine was proven effective in
acquired cold urticaria.24
Led by the plausible statement of Allen Kaplan that
defining the level of refractoriness to antihistamines is the key
to effective therapy, we carried out a study to check if a dose
increase of the modern second-generation H1 receptor antag-
onists desloratadine and levocetirizine of up to fourfold could
increase the success rate of treatment of chronic urticaria and
improve the health-related quality of life without compromis-
ing safety.25 We recruited 80 patients with difficult-to-treat
chronic urticaria defined on the basis of referral to our tertiary
specialist clinic after previous treatment failures, and, after
documentation of their subjective symptoms and quantifica-
tion of the objective findings, randomized them to receive in
a double-blind crossover fashion increasing doses of either
levocetirizine (40 patients) or desloratadine (40 patients) at
1-week intervals. The primary outcome was the number of
patients becoming symptom-free (no subjective symptoms
and no urticarial lesions) at the different dosing steps; the
secondary outcomes included assessment on 100-mm visual
analog scales of the discomfort because of urticaria and the
level of sedation/somnolence, and the quality of life evalu-
ated by means of Chronic Urticaria Quality of Life Question-
naire.26 The results demonstrated that the number of patients
rated as having treatment success significantly increased
(more than doublefold) at doses higher than the conventional
5-mg dose (Fig. 2).
A common belief is that patients might respond to one
or another AH depending on their specific phenotype, rather
than on the pharmacological characteristics of the different
formulations. This type of reasoning prompts switching from
one drug to another and also simultaneous intake of different
AH. In a preceding study we compared the ability of increas-
ing doses of levocetirizine and desloratadine to suppress the
effects of intradermal histamine in healthy men.27 The results
indicated that levocetirizine is significantly more effective
than desloratadine in inhibiting the wheal and flare responses
to histamine in human skin in vivo, with 1.25 mg of levoce-
tirizine being more effective than 10 mg of desloratadine.
This superior effectiveness of levocetirizine in the skin was
confirmed in our above-described clinical study in chronic
urticaria patients, in which 7 patients who failed to respond to
20 mg of desloratadine became symptom-free on levocetiriz-
ine, whereas none of the fewer therapeutic failures at 20 mg
of levocetirizine benefited from the switchover to 20 mg of
desloratadine. The higher efficacy of levocetirizine than that
of desloratadine in CIU was also confirmed in a multicenter
study of 886 patients using only the standard 5-mg dosage.28
The relationship between subjective perceptions like
discomfort because of urticaria, sedation/somnolence, and
disease-specific quality of life is rather complex. On the basis
of the relief of the discomfort because of urticaria, we could
differentiate “low-dose responders,” approximately 10% of
the patients who responded to the standard dose of 5 mg,
“nonresponders,” about 15% who did not experience any
improvement even at the highest 20-mg dose, and “high-dose
responders,” ranging in the gray zone between those 2 ex-
tremes making up 75% of the patients.25 In the majority of
patients somnolence (measured on a 100-mm visual-analog
scale at baseline and after each treatment step) did not change
or decreased in the course of the incremental treatment. This
finding was better expressed with levocetirizine, where also a
significant correlation shaped up between the positive change
in the perception of urticaria discomfort and the reduction of
somnolence. The analysis of the quality of life questionnaires
revealed improvement with the increasing doses of both
drugs, still better outlined with levocetirizine.
CONCLUSIONS
The quoted study and the experience we have acquired
during the past years in the treatment of chronic urticaria give
us ground to believe that high enough doses of nsAH give the
best chance of achieving control of the urticaria symptoms
before resorting to other potentially more hazardous ap-
proaches. The higher doses of these drugs may also be
associated with additional anti-inflammatory effects29 that
may be relevant for many cases of chronic urticaria. Present
and future formulations with the highest affinity for the skin
should be given preference in more severe cases of chronic
urticaria. The controversy about the use of first-generation
FIGURE 2. Results of the study of higher than conven-
tional doses of levocetirizine and desloratadine in difficult-to-
treat urticaria (adapted from Staevska et al25). The darkened
boxes represent the successes at conventional doses for both
drugs and the light boxes represent the additional value of
dose increase.
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versus second-generation H1 AH in chronic urticaria could be
given an ultimate answer only if specifically designed com-
parative studies are carried out.
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